Oral Anticoagulation in Patients with Chronic Liver Disease

Area of Science:

• Hepatology
• Cardiology
• Pharmacology

Background:

• Anticoagulant therapy in liver disease presents a challenge due to the thrombosis-bleeding imbalance.
• Risk factors like diabetes, obesity, and smoking are common in patients with nonalcoholic steatohepatitis (NASH)/nonalcoholic fatty liver disease (NAFLD) requiring anticoagulation.
• Vitamin K antagonists (VKAs) are currently recommended for advanced liver disease (Child-Pugh C) due to study exclusions.

Purpose of the Study:

• To review the current landscape of anticoagulant use in patients with liver disease.
• To evaluate the safety and efficacy of direct oral anticoagulants (DOACs) compared to VKAs in this population.
• To identify gaps in current research and recommend future study directions.

Main Methods:

• Review of existing literature on anticoagulant use in patients with various liver conditions (NASH, NAFLD, chronic hepatitis, cirrhosis).
• Analysis of clinical trial data comparing DOACs (e.g., apixaban) and VKAs (e.g., warfarin).
• Assessment of DOAC safety and efficacy across different liver function classes (Child-Pugh A, B, C).

Main Results:

• DOACs demonstrate efficiency and safety, with apixaban showing superior stroke protection and a favorable bleeding profile versus warfarin.
• DOACs are considered safe in Child-Pugh A and B liver disease (excluding rivaroxaban in some cases), but are contraindicated in Child-Pugh C.
• Warfarin use, particularly in the elderly, is associated with significant bleeding events and emergency admissions.

Conclusions:

• DOACs offer advantages like simpler administration, fewer drug interactions, and improved patient compliance.
• While DOACs are promising for liver disease patients, further randomized studies are essential to clarify their role, especially in impaired liver function.
• Current recommendations still favor VKAs for advanced liver disease (Child-Pugh C) due to limited data on DOACs in this group.